RON Clocks Five-Year Cancer Survival in Portugal at 66% for the 2019 Cohort — Women Sit 10 Points Above Men, Thyroid and Testicular Tumours Clear 90% and Madeira Trails the Mainland

The Registo Oncológico Nacional (RON) on Monday 19 May 2026 pegged five-year cancer survival in Portugal at 66% for the 54,147 malignant tumours diagnosed across the country in 2019, with the headline number papering over a 10-point gap between women and men and a stubborn outcomes gulf between the mainland and Madeira. The reading, drawn from the central tumour registry coordinated out of IPO-Porto, is the first systematic Portuguese cohort comparable to the EUROCARE methodology and arrives with the policy debate over continuing care for older patients already on the table.

Women carry a 72% five-year survival rate against 62% for men — a spread Maria José Bento, the RON coordinator, attributes to the male share of lung, larynx and oral-cavity cancers, all sitting deep in the poor-prognosis column. Six tumour families clear the 90% mark: thyroid, testicular, prostate, Kaposi sarcoma, breast and the chronic myeloproliferative cluster. At the other end, five tumour groups stay below 20%: brain and central nervous system, mesothelioma, esophageal, pancreatic, and cancers of primary unknown origin.

The data, point by point

• Cohort: 54,147 malignant tumours diagnosed in 2019, ex non-melanoma skin cancers, metastases and recurrences.
• Overall five-year net survival: 66%.
• By gender: Women 72%, Men 62% — a 10-percentage-point gap.
• Best prognosis (>90%): Thyroid, testicular, prostate, Kaposi sarcoma, breast, chronic myeloproliferative diseases.
• Worst prognosis (<20%): Brain and CNS, mesothelioma, esophageal, pancreatic, primary unknown origin.
• By region: North and Centre lead; Madeira is the worst-performing area.
• By age: The over-75 bracket sits at 56.8%.

Why the regional gulf matters

Madeira's lagging numbers reflect referral logistics — patients with rarer or complex tumours travel to mainland centres for second-line care, and any pause in the pathway shows up downstream in five-year survival. The over-75 cohort's drag confirms what palliative-care leaders have flagged for years: late-life diagnoses combined with capacity friction in the SNS continuing-care chain compress treatment windows. The release also lands two days after Infarmed's 2025 SNS medicine read, which booked oncology drug spend at €864.5 million — up 16% year-on-year and the single fastest-growing therapeutic line.

What this means for expats and residents

• SNS pathway: The 66% headline pools SNS and private patients, so the numbers describe Portugal's delivered outcomes — not best-case private marketing.
• Screening pays: Breast, prostate, thyroid and testicular cancers cleared 90% precisely because the diagnostic signal is loud and treatment starts early. SNS breast and colorectal programmes remain free at point of care.
• Regional choice: If you live in Madeira, the Azores or far from an IPO catchment, the data argues for early referral to a mainland tertiary centre for rarer cancers.
• Drug-access timing: The 66% number reflects 2019 treatment; the latest immuno-oncology and targeted-therapy classes are not yet in the cohort. The 650-day gap between EU authorisation and SNS funding is the structural drag the next cohorts will inherit.
• Private top-up: The EY-Parthenon read books €1.945 billion of SNS savings from private cover in 2023; for oncology, the private route often shortens the diagnostic window even when the treating hospital is back inside the SNS.

Bento told reporters the RON will publish updated cohort data annually, with 2020 diagnoses up next. The structural question is whether cohorts touched by PRR-funded screening expansion and post-2024 immuno-oncology rollouts close the gap with Northern European benchmarks — or whether the gender and regional spreads survive another full treatment cycle.